Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries Ltd: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Pediatric Medicine 2018

Market Analysis

The global market for pediatric medicine was around $83.6 billion in 2014, potentially rising by about 4% annually until 2019 reaching $100.7 billion. Among the booming market rise categories Vaccines, inflammatory diseases, respiratory conditions and viral infections are key therapy areas, in addition to central nervous system (CNS) treatments and oncology. Obesity, conjointly with diabetes in later life, is a special concern (as well as for Type I diabetes itself, generally a childhood condition). Moreover, the growth of specialty drugs under the Orphan Drug Act has been an added boon for pediatric medicine with children being the most preys to rare diseases. Orphan drug diseases have also provided new opportunities for the industry to target pediatric drugs to treat childhood cancers, metabolic diseases and immune-related diseases. Pediatric medicine market’s significant rise through 2019 can be attributed to the industry becoming more familiar with designing and implementing trials in the pediatric population. In addition, the focus on commercially viable targets of high unmet clinical needs such as diseases designated under the Orphan Drug Act (ODA), those for pediatric oncology and the treatment of metabolic disorders.

However, surveys say that when assessing for clinicians prescribing a medicine which is off-label to a pediatric patient, 20% of physicians don’t inform the parent or guardian that they are doing so, and only 24% of physicians require legal consent. Thus it is evident that there is an increased risk of malpractice lawsuits without informed consent.

Reports say that researchers who have studied the impact of hospital medicine in 12 U.S. cities have found a “stunning” level of variation. The researchers were surprised at different models hospitalist programs carried out around the country. To their surprise different types of hospitalist programs function side by side in single markets. Nevertheless, when it comes to utilizing hospitalists, the American Hospital Association reported that 60 percent of hospitals staff these specialists today, up from only 30 percent 10 years ago.


Track 1: Clinical conundrums

Pediatric clinical conundrums are some interesting topics of discussion for clinicians around the world. More than theoretical approach a real time case study or case report is more effective to deal with critical situations arising in the hospital. This session will focus on all such case studies and real experiences of paediatricians and other physicians in the hospital. A systematic approach towards better pediatric healthcare will be the main aim of this conference session.

Track 2: Pediatric and hospital medicine specialties

The American Academy of Pediatrics(AAP) started the section on Hospital Medicine with approximately just over 400 members in the year 2005 and presently with the rise in importance of this speciality now has over 2,000 members. With the sole outlook and motive of transitioning patients safely back into the community at the time of their discharge is the aim of every hospitalist. The inpatient teams consisting several sub-specialities and including the patient, family and social and other services coordinate to form an interdisciplinary plan of healthcare that is necessary.This session of the conference will aim to associate with such care givers who are instrumental in providing the best and required treatments to the patients.

Track 3: Challenges in Pediatric drug development

Pediatric drug development is a challenge for over the past half a century. There are quite a few childhood diseases which have significant occurrence rates in pediatric subjects but  for which there are no approved drugs. Reports say that as a result of low prioritization of pediatric drug development globally about 75% of drugs do not carry regulatory approval for use in infants or children; ~66% of medications used in children in the US are used off label, 50% in Europe and in Japan it is less than 20%. Most medications in these regions donot contain package inserts have adequate information for treating infants or children. This session will address all such issues including R&D, F&D and regulatory framework with research scientists from different pharmaceutical industries and also drug discovery researchers.

Track 4: Pediatric drug delivery and dosage forms

A different or modified drug delivery system is required by the pediatric patients compared to other subsets of the population due to their continuing development hence dosing and administration requirements. Conventional formulations are not designed for pediatric patients. Hence it becomes necessity to manipulate and compound the medication accordingly and this has become common practice. The pharmacokinetic and pharmacodynamic profile of a drug varies broadly depending on the factors like developmental stage of a child, necessitating dose flexibility to suit the dosing requirements etc. Excipients which are commonly regarded as safe may pose a safety risk for child group in addition to other considerations of the formulation and development of the dosage form a drug. Palatability and ease of swallowing are also considered as pivotal parametrs for the acceptability of medicines intended for children, who due to their age possess distinct preferences and swallowing abilities than other subsets of the population. New formulation design approaches like multiparticulate drug delivery systems, orodispersible tablets (ODTs), orodispersible films (ODFs), and chewable formulations are gainig importance based on their respective efficacy, PK/PD factors and patient compliances.

To Collaborate Scientific Professionals around the World

Conference Date August 31- September 01, 2018

For Sponsors & Exhibitors

Speaker Opportunity

Supported By

Pediatrics & Therapeutics Clinical Pediatrics: Open Access

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by


  • Admitologist
  • Air Embolism
  • Allied Health Professionals
  • Antifungal Therapy
  • Antiviral Therapy
  • Arterial And Venous Blood Drawing
  • Blood Culture Collection
  • Blood Incompatibility
  • Catheter-Associated Urinary Tract Infection (UTI)
  • Causative Organisms And Control
  • Challenges And Opportunities For The Future
  • Challenges In Developing And Prescribing Drugs For Children
  • Chewable Tablets
  • Coated Tablets
  • Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE) Following Certain Orthopedic Procedures:
  • Diabetic Ketoacidosis
  • Differences In Drug Metabolism
  • Differences In Drug Response
  • Differences In Toxicity Profiles
  • Dispersible And Effervescent Tablets
  • Dosage Form Suitability
  • Efficiency
  • Endotracheal Intubation
  • Equity
  • Essentials Of Pediatric Nursing
  • Ethanol Lock Therapy (ELT)
  • Exchange Transfusion
  • Falls And Trauma
  • Foreign Object Retained After Surgery
  • Hospital Acquired Conditions
  • Hospitalists: Categorization
  • Iatrogenic Pneumothorax With Venous Catheterization
  • Lumbar Puncture
  • Manifestations Of Poor Glycemic Control
  • Medical Students
  • Meropenem And Moxifloxacin
  • Models For Enhancing Pediatric Drug Development
  • Neonatal-Perinatal Medicine
  • Neurohospitalist
  • Nocturnist
  • Nosocomial Bacteraemia
  • Nosocomial Pneumonia
  • Nurse Practitioners & Physician Assistants
  • Orally Disintegrating Tablets
  • Other Nosocomial Infections
  • Patient Compliance
  • Patient Safety
  • Patient-centered Care
  • Pediatric Allergy
  • Pediatric And Hospital Medicine Specialities
  • Pediatric Cardiology
  • Pediatric Care
  • Pediatric Care
  • Pediatric Dose Administration
  • Pediatric Dosing
  • Pediatric Drug Delivery And Dosage Forms
  • Pediatric Drug Discovery Challenges
  • Pediatric Emergency Medicine
  • Pediatric Endocrinology
  • Pediatric Gastroenterology
  • Pediatric Genetics And Metabolism
  • Pediatric Hematology
  • Pediatric Hepatology
  • Pediatric Hospitalist Responsibilities
  • Pediatric Hospitalization Process Improvement Techniques
  • Pediatric Immunology
  • Pediatric Nephrology
  • Pediatric Nosocomial Infections
  • Pediatric Nosocomial Infections: Diagnosis And Treatments
  • Pediatric Nursing And Care
  • Pediatric Nursing Education
  • Pediatric Oncology
  • Pediatric Pulmonology
  • Pediatric Rheumatology
  • Penicillin, Gentamicin, And Metronidazole (PGM) Combination Therapy
  • Percutaneous Venous And Arterial Line Placement
  • Physicians
  • Powders For Reconstitution As Suspension
  • Proceduralist
  • Regulatory Framework
  • Residents/Fellows
  • Rounder
  • Route Of Administration
  • Solution- Syrups, Elixir
  • Sprinkle Oral Powder Or Granules
  • Stage III And IV Pressure Ulcers
  • Suprapubic Tap
  • Surgical Site Infection Following Bariatric Surgery For Obesity
  • Surgical Site Infection Following Cardiac Implantable Electronic Device (CIED)
  • Surgical Site Infection Following Certain Orthopedic Procedures
  • Surgical Site Infection, Mediastinitis, Following Coronary Artery Bypass Graft (CABG):
  • Surgical Site Infections
  • Surgicalist
  • Suspension
  • Thoracecentesis
  • Timeliness
  • Treatment Effectiveness
  • Umbilical Catheterization
  • Urinary Infections
  • Vancomycin Treatment
  • Vascular Catheter-Associated Infection